undamentalytics Newsletter
Sign in

Kymera Therapeutics, Inc. cash flow statement

In fiscal 2025, Kymera Therapeutics, Inc.'s operations generated −$233m of cash; it spent $1.4m on capital projects, leaving free cash flow of −$234m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations1888−129−153−103−195−233−288
Depreciation and amortisation12234787
Stock-based pay15253543556068
Capital spending1923341311
Free cash flow1779−131−156−137−207−234−289
Free cash flow after stock pay1674−156−191−180−262−294−357

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KYMR vs XNCRKYMR vs SEPNAGIO vs KYMR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kymera Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kymera Therapeutics, Inc.